{
  "parties": [
    "KIROMIC BIOPHARMA Inc., a Delaware Company, Fannin South Professional Building, 7707, Fannin St. Suite 140, Houston TX 77054 USA, in person of the Legal Representative of the Chief Executive Officer dr. Prof. Maurizio Chiriva Internati, PhD",
    "MOLIPHARMA S"
  ],
  "effective_date": null,
  "governing_law": null,
  "payment_terms": null,
  "termination_clause": {
    "text": "Termination of this JV Agreement shall not relieve the Parties of their obligations due at the time of such termination, nor shall such termination prejudice any claim of either Party accrued, or to accrue, on account of any default or breach by the other Party. 9. WITHDRAWAL AND RESOLUTION\n\nThe Parties may withdraw from this JV only for serious and justified reasons or by mutual consent. The withdrawal must be exercised by written notice, to be sent to the other Party by certified letter or PEC, with minimum notice of 30 days.\n\nWithdrawal or termination by mutual consent shall only have effect for the future and shall not affect the part of the Agreement already executed.\n\nIn case of withdrawal according to the previous paragraph, Kiromic is obliged to cover Molipharma for the expenses incurred and",
    "start": 16331,
    "end": 17142,
    "confidence": 0.72,
    "source": "regex"
  },
  "_doc_id": "KIROMICBIOPHARMA,INC_04_08_2020-EX-10.28-JOINT VENTURE AGREEMENT.txt",
  "_char_count": 36610,
  "_provenance": {}
}